Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AB-106
AB-106, digoxin · 2 trials · 1 indication
Peak Plasma Concentration (Cmax)
Area under the plasma concentration versus time curve (AUC)
| Arm | Type | Description |
|---|---|---|
| Itraconazole cohort | EXPERIMENTAL | - |
| Rifampicin cohort | EXPERIMENTAL | - |
| digoxin cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AB-106, Itraconazole | DRUG | single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17 |
| AB-106, Rifampicin | DRUG | single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21 |
| AB-106, digoxin | DRUG | Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin |
Inclusion Criteria: 1. The subject is willing to give written informed consent. 2. The subject is capable to communicate well with investigator and comply with comply with protocol throughout the study. 3. Aged between 18 to 55 at giving written informed consent. 4. Chinese male healthy subjects (N...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AB-106 is an investigational small molecule being developed for oncology indications, specifically non-small cell lung cancer (NSCLC) and solid tumors. It is currently in Phase 2 clinical development for advanced NSCLC harboring ROS1 fusion gene, and has also been studied in healthy volunteers for pharmacokinetic effects.
AB-106 is being developed by Nuvation Bio Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol NUVB. The company is conducting clinical trials for this investigational oncology drug.
AB-106 is in Phase 2 clinical development. The most advanced trial is a Phase 2 study in patients with advanced non-small cell lung cancer harboring ROS1 fusion gene, which is active but not recruiting. Earlier Phase 1 studies have been completed.
AB-106 has been studied in three clinical trials. The main trial is NCT04395677, a Phase 2 study in 173 patients with advanced NSCLC harboring ROS1 fusion gene in China. Two Phase 1 studies, NCT05357820 and NCT05357911, evaluated drug interactions in healthy volunteers and have been completed.
AB-106 is not FDA approved. It is an investigational drug currently in clinical development. The most advanced trial is a Phase 2 study in non-small cell lung cancer, which is active but not recruiting. No approval status has been reported.
AB-106 targets the ROS1 fusion gene in non-small cell lung cancer. The Phase 2 clinical trial specifically enrolls patients with advanced NSCLC harboring ROS1 fusion gene, indicating that the drug is designed to act on this molecular target.